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 18 
Abstract  19 
3D printed microneedle arrays were fabricated using a biocompatible resin through 20 
stereolithography (SLA) for transdermal insulin delivery. Microneedles were built by 21 
polymerising consecutive layers of a photopolymer resin. Thin layers of insulin and sugar 22 
alcohol or disaccharide carriers were formed on the needle surface by inkjet printing. The 23 
optimization of the printing process resulted in superior skin penetration capacity of the 24 
3D printed microneedles compared to metal arrays with minimum applied forces varying 25 
within the range of 2 to 5N. Micro–CT analysis showed strong adhesion of the coated films 26 
on the microneedle surface even after penetration to the skin. In vivo animal trials revealed 27 
fast insulin action with excellent hypoglycaemia control and lower glucose levels achieved 28 
within 60 min, combined with steady state plasma glucose over 4 h compared to 29 
subcutaneous injections.  30 
 31 
Introduction 32 
Transdermal Drug Delivery (TDD), the ability to effectively convey drugs through the human 33 
skin, is an appealing concept, aiming at surpassing the pitfalls of the traditional administration 34 
routes. The broader adoption of the transdermal route, however, is hampered by restrictions that 35 
stem from the nature of the skin barrier itself, especially by the stratum corneum. Microneedles 36 
(MNs) are small devices that can pierce this outermost, most impermeable layer of the human 37 
skin and successfully deliver active substances such as drugs, Ribonucleic acid (RNA), 38 
Deoxyribonucleic acid (DNA), and vaccines straight into the dermal microcirculation [1–4] . 39 
Due to their small size they leave skin nerves intact upon insertion [5], while they increase 40 
3 
 
bioavailability since the drug does not pass through any metabolic systems [6]. The MN-41 
mediated drug delivery is realised through multiple strategies that employ solid, coated, hollow, 42 
hydrogel-forming and soluble MNs [7]. 43 
Since their introduction over 20 years ago, MN systems have attracted significant attention for 44 
their potential to replace traditional drug administration routes. In the field of diabetes type 1 and 45 
some types of type 2, the vast majority of patients rely on subcutaneous needle injections for 46 
insulin replacement, a treatment approach highly associated with reduced patient-compliance [8]. 47 
Pain, skin thickening due to recurring injections, needle phobia and insulin leakages on the skin 48 
surface [9,10] have motivated vigorous research on MN-based systems for transdermal insulin 49 
delivery. 50 
Recent advances encompass the use of moulding techniques for the development of insulin-51 
loaded dissolvable MN systems. Wang et al. introduced a bioinspired MN system consisting of 52 
dissolvable cross-linked poly(vinyl alcohol) (PVA) gel, catalase and glucose oxidase (GOx) that 53 
responds to high glucose conditions by releasing insulin to the circulation. In vivo tests showed 54 
that the systems were effective in maintaining normal blood glucose levels [11]. In another 55 
study, modified alginate and hyaluronate were combined into a dissolvable, insulin-56 
encapsulating MN system. The MN arrays demonstrated good mechanical properties and skin 57 
penetration capability while clinical studies demonstrated that the MNs almost fully dissolved 58 
into the skin. The released insulin achieved a sustained hypoglycaemic effect and good relative 59 
bioavailability of insulin, compared with subcutaneous injections [12]. Similar results in terms of 60 
mechanical properties, relative insulin bioavailability and pharmacological activity were also 61 
obtained by a study that manufactured composite dissolvable MNs [13]. The forenamed studies 62 
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demonstrate that MN can be a promising alternative to subcutaneous injections for insulin 63 
therapy.  64 
Nonetheless, there are several hampering parameters that need to be taken under consideration 65 
for the development of transdermal insulin delivery systems. The first relates to the time needed 66 
for the detection of the drug into the systemic circulation; dissolvable systems are highly 67 
dependent on the dissolution rate of the materials encapsulating the drug and may not be suitable 68 
for fast insulin administration. To circumvent that issue, Ross et al. developed a solid MNs-69 
based system, coated with insulin-containing formulations through inkjet printing [14]. The use 70 
of this technology permitted the accurate deposition of uniform and homogeneous coatings, with 71 
high reproducibility. The implementation of inkjet printing for the development of thin layers on 72 
the microneedle surface resulted in rapid insulin release within the first 20 min. 73 
Another pitfall stems from the use of moulding techniques, that involve a series of multiple, 74 
often time-consuming steps. It is evident, that the upscaling of such processes can be 75 
challenging. Furthermore, there is a lack of clinical data related to cytotoxicity of materials used 76 
for moulded microneedles which actually limits their applications. Another important 77 
disadvantage is the limited drug loading in polymeric microneedles without affecting their 78 
mechanical properties and piercing capacity. In order to circumvent this issue several authors 79 
proposed the use of large patches which in turn results in difficulties to apply the arrays in a 80 
uniform manner and subsequently in dose variation of the administrated substances.  Recently, 81 
efforts have been made on the integration of the revolutionary technology of 3D printing as a 82 
manufacturing method for MN-based systems. 3D printing or Additive Manufacturing (AM) is a 83 
family of technologies that implement layer-by-layer processes to fabricate physical models, 84 
based on a Computer Aided Design (CAD) model. 3D printing permits the fabrication of high 85 
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degrees of complexity with great reproducibility, in a fast and cost-effective fashion [15–18]. In 86 
the field of transdermal drug delivery systems, the use of photopolymerization-based techniques 87 
such as Stereolithography (SLA), Digital Light Processing (DLP) and Two-Photon-88 
Polymerization (2PP) for the development of MNs has been reported [19–22]. Gittard et al. 89 
fabricated MNs of various geometries for wound healing applications using a DLP system. The 90 
MNs were then coated with silver and zinc oxide thin films by pulse laser deposition and their 91 
antimicrobial character was verified [23]. In another study, drug-loaded MNs were developed 92 
when a skin anticancer drug was incorporated into the photo-sensitive polymer blend prior to 93 
photopolymerization through a micro-stereolithographic (DLP) apparatus [24]. 94 
In this study, 3D printed MN arrays featuring two different MN designs, pyramid and spear, 95 
were developed employing a commercial SLA printer and a biocompatible Class 1 polymer. The 96 
3D printed arrays were subsequently coated with insulin–sugar films using inkjet printing. 97 
Mannitol, trehalose and xylitol were used as insulin carriers to preserve insulin activity prior to 98 
the deposition of active films on the MNs surface. In vitro and in vivo studies demonstrated rapid 99 
insulin release from the coated MN systems. The usage of SLA for 3D printing of microneedle 100 
arrays is anticipated to overcome the existing disadvantages of conventional techniques by 101 
providing high precision, rapid fabrication, reduced processing steps and freedom to print a wide 102 
range of shapes.  103 
Materials and methods 104 
Materials 105 
The insulin employed in this study was bovine and was procured in a 10 mg mL-1 solution from 106 
Sigma-Aldrich (Gillingham, UK). Xylitol (Xylisorb 90) and mannitol (Pearlitol) were 107 
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donated by Roquette Freres (France) while trehalose dihydrate was bought from Sigma-Aldrich 108 
(Gillingham, UK). The resin used to fabricate the MNs was the biocompatible Class I resin, 109 
Dental SG, by Formlabs. Streptozocin (≥75% α-anomer basis, ≥98%) and citric acid were both 110 
purchased from Merck Chemical Co. (Darmstadt, Germany). All solvents were of analytical 111 
grades. 112 
 113 
Additive manufacturing of microneedles 114 
The MN arrays were designed using an engineering software (SolidWorks, Dassault Systems) as 115 
patches of 15x15x1 mm. The patches featured two different needle shapes, a pyramid and a flat 116 
spear shaped that geometrically resembled the shape of metallic MNs that has been studied 117 
elsewhere [16]. This design, named ‘spear’ in the framework of this study, had base dimensions 118 
of 0.08x1 mm, while the dimensions of the base for the pyramid MN were 1x1 mm. The length 119 
of all MNs was 1 mm and all patches had a 6x8 needle layout, yielding 48 MNs per patch. The 120 
arrays were 3D printed using the Form 2 SLA printer by Formlabs with high resolution 121 
capabilities (25 and 140 microns for z and x axes, respectively). After fabrication, the arrays 122 
were washed in isopropyl alcohol bath to remove unpolymerized resin residues and then cured 123 
for 60 min at 40 oC under UV radiation using the MeccatroniCore BB Cure Dental station. 124 
Coating of microneedles through inkjet printing 125 
An inkjet printer was employed (NanoPlotter II, Gesim, Germany) to print thin insulin-sugar 126 
films on the surface of the 3D printed MNs. The inkjet printer forms the drug-containing films 127 
depositing multiple layers of insulin – sugar droplets on each microneedle using a piezo-driven 128 
dispenser (PicPip 300). In each coating cycle (layer), the dispenser jetted 2 droplets of 129 
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formulation in 10 spots along each needle’s longitudinal axis. A total of 92 coating cycles 130 
resulted in a 10 UI (350 µg) of insulin per array. The coated arrays were then incubated at room 131 
temperature for 24 hours to allow the evaporation of the solvent (de-ionised water) and the 132 
formation of uniform films. For the purposes of this study three coating formulations were used, 133 
consisting of insulin:xylitol (5:1 wt/wt), insulin: mannitol (5:1 wt/wt) and insulin:trehalose (5:1 134 
wt/wt) as 2% solid content. Prior to the coating process, the arrays were mounted on a metal stub 135 
at 45o relative to the dispenser, while its tip (50 m) was placed close to the MN surface to avoid 136 
losses of material. 137 
Scanning electron microscopy (SEM) 138 
The coated MN arrays were mounted onto aluminium stubs using a double-sided carbon 139 
adhesive tape (Agar Scientific, UK). Each coated MN array was examined by SEM (Hitachi SU 140 
8030, Japan) using a low accelerating voltage (1.0kV). A low accelerating voltage was used to 141 
avoid electrical charges on the MNs. The images of coated MNs were captured digitally from a 142 
fixed working distance (11.6 mm) using different magnifications (e.g. 30, 80, 110 or 120 x). 143 
X-Ray Computer Micro Tomography 144 
X-Ray Micro Computer Tomography (μCT) scans were performed on coated 3D printed 145 
pyramid MN. The equipment employed was a Bruker Skyscan 1172, with an SHT 11 Megapixel 146 
camera and a Hamamatsu 80kV (100μΑ) source. The samples comprised of 3D printed pyramid 147 
MN coated with the three insulin/sugar formulations; Sample A: insulin:xylitol (5:1 wt/wt), 148 
Sample B: insulin: mannitol (5:1 wt/wt) and Sample C: insulin:trehalose (5:1 wt/wt). After the 149 
scans of the coated arrays were performed, the arrays were inserted in 8-ply strips of parafilm, 150 
applying a force of 5 N, to examine the performance of the coating during piercing and to 151 
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investigate whether any coating material will remain on the parafilm surface, causing drug 152 
losses. Moreover, the penetration depth was measured. The samples were mounted vertically on 153 
a portion of dental wax and positioned 259.4 mm from the source. No filter was applied to the X-154 
Ray source and a voltage of 80 kV was applied for an exposure time of 1,050 ms. The images 155 
generated were 2,664 x 4,000 pixels with a resolution of 6.75 μm per pixel.  156 
A total of 962 images were taken in 0.2o steps around one hemisphere of the sample with the 157 
average of 4 frames taken at each rotation step. The images were collected and a volumetric 158 
reconstruction of the sample generated by Bruker’s CTvol software. The threshold for this 159 
attenuation signal was set manually to eliminate speckle around the sample, and then further 160 
cleaned with a thresholding mask using Bruker’s CTAn software. The images produced by the 161 
μCT are based on the level of attenuation though the sample, which is dependent on the thickness 162 
of the material and its absorption coefficient. Here, it is assumed that the absorption coefficient is 163 
linearly proportional to the density of the material and the resulting densities expressed in 164 
Hounsfield Units (HU), with -1000 being the density of air and 0 being the density of water. 165 
Circular Dichroism (CD) 166 
Insulin solution and the respective solutions of the insulin-sugar films were diluted to 1.0 mg 167 
mL-1 in deionised water and the spectra were recorded at 20 ºC between 190 and 260 nm by CD 168 
(Chirascan, Applied Photophysics, UK) using a 0.1 mm polarization certified quartz cell 169 
(Hellma). Spectra were recorded using a step size of 1 nm, a bandwidth of 1 nm and an 170 
acquisition time of 1 sec. Four scans were recorded for each sample, averaged and a 171 
corresponding spectrum of water was subtracted from each spectrum. For estimation of the 172 
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secondary structural composition of insulin, the CD spectra were evaluated using the CD SSTR 173 
method [25]. 174 
Raman Spectroscopy 175 
The films and their respective components were analysed using Raman microscopy (Jobin Yvon 176 
LabRam I) with a laser of 532 nm wavelength coupled with an optical microscope with 50x 177 
objective. 178 
Penetration studies through porcine skin 179 
The effect of the MN geometry on the force required to pierce the skin has been documented 180 
[26]. In this study, to determine the effect of needle shape on the force required for skin 181 
penetration, piercing tests using porcine skin were conducted. Identical piercing tests were 182 
carried out using metallic MN arrays that have been studied and are described in literature [16], 183 
to maintain a frame of reference with the respective studies. A texture analyser was employed, 184 
and the MN array was mounted on the moving probe using double-sided adhesive tape. Prior to 185 
testing, the porcine skin samples were placed in waxed petri dishes. Continuous force and 186 
displacement measurements were recorded to identify the point of needle insertion. The speed of 187 
the moving probe was 0.01 mm s-1. 188 
Axial force mechanical testing of MNs 189 
To evaluate the mechanical behaviour of the 3D printed microneedles, fracture testing under 190 
axial loading was performed. The arrays were fixed onto a metal plate and were pressed against a 191 
flat metal block attached to the moving head of a Tinius Olsen testing machine, until a pre-set 192 
displacement of 500 μm (height/2) was reached. Continuous force and displacement 193 
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measurements were recorded to identify the point of needle failure. The speed of the moving 194 
probe was 1 mm/s and the experiments were replicated 5 times for each design. 195 
Preparation of porcine skin for in vitro release of insulin 196 
The release of insulin from the coated MNs through abdominal porcine skin was studied using 197 
Franz diffusion cells (PermeGear, Inc., PA, USA). The full thickness abdominal porcine skin 198 
was collected from a local slaughterhouse (Forge Farm Ltd, Kent, UK) and was then shaved 199 
using a razor blade. The fatty tissue below the abdominal area of porcine skin was removed with 200 
scalpel and then pinned onto polystyrene block and wiped with 70 % ethanol. The skin was then 201 
cut by applying the dermatome at an angle of ±45° (Padgett dermatome, Integra LifeTMSciences 202 
Corporation USA). The thickness of the skin was measured by using a calliper and the tissue 203 
disks of the required dimensions were cut for the Franz diffusion cells using a scalper. The skin 204 
tissue (1.0 ± 0.1 mm thick) was placed onto filter paper soaked in a small amount of saline 205 
phosphate buffer (pH 7.4) for 2 h.  206 
In vitro release of insulin through porcine skin 207 
A total diffusion area of 1.1 cm2 was used to assess the insulin release. The MN arrays were 208 
inserted into the abdominal porcine skin samples for 30 s, via manual finger pressure. The 209 
sample was then mounted onto the donor compartment of a Franz diffusion cell. The temperature 210 
of the Franz cells was maintained at 37ºC using an automated water bath (Thermo Fisher 211 
Scientific, Newington, USA). Sample fractions (6-6.5 mL h-1) were collected using an auto-212 
sampler (FC 204 fraction collector, Gilson, USA) attached to the Franz diffusion cells system. 213 
Statistical analysis for the drug release was performed by using a Mann-Whitney nonparametric 214 
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test and t-test analysis for the in vivo studies (InStat, GraphPad Software Inc., San Diego, CA, 215 
USA), where samples were considered as statistically significant at p < 0.05. 216 
High-Performance Liquid Chromatography (HPLC) 217 
The amount of insulin collected from the receptor fluid was determined by HPLC (Agilent 218 
Technologies, 1200 series, Cheshire, UK) equipped with a Phenomenex Jupiter 5u c18 300 Å, 219 
LC Column (250×4.60 mm, particle size 5 μm, Macclesfield, UK). The mobile phase consisted 220 
of water with 0.1 % Trifluoroacetic Acid (TFA) and acetonitrile with 0.1% TFA (66:34v/v), with 221 
a 1 mL min−1 flow rate. The column was equilibrated at 35°C, the injection volume was 20 μL 222 
and the eluent was analysed with a UV detector at 214 nm. The results were integrated using 223 
Chemstation® software and the samples analysed in triplicates. 224 
In vivo release in diabetic mice 225 
Prior to the induction of diabetes, Swiss albino female mice (120 ± 10 g) were allowed free 226 
access to solid bottom cages with controlled diet and water for 3 days. Mice were subcutaneously 227 
injected on the flank with streptozotocin (70 mg kg-1) in citric acid buffer (pH 4.5) to produce a 228 
diabetic animal model. To confirm the induction of diabetes, the fasting blood glucose level was 229 
measured at scheduled times using a one-touch glucometer (ACCU-CheckVR Active, Roche, 230 
Germany). After one week, mice with blood glucose exceeding 300 mg/dl were considered as 231 
diabetic. The diabetic animals were anesthetised and shaved carefully using an electric razor 232 
(Panasonic, USA) 24 hours prior to the experiments. Furthermore, the diabetic mice were fasted 233 
for 12 hours before the beginning of the study, receiving only water and libitum. The mice were 234 
randomly divided into three groups (n=3 for each group): (1) untreated group as negative control; 235 
(2) subcutaneous injection (SC; 0.2 IU/animal) as positive control; (3) 3D printed MN (0.2 236 
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IU/array). The 3D printed MN arrays were applied onto the dorsal skin of the animals using 237 
adhesive tape (3M, USA) to prevent any dislodgement during therapy. After 2 hours, the 3D 238 
printed MN patches were removed. For all groups, blood samples were collected from the 239 
jugular vein at 0, 1, 2, 3 and 4 hours after the insulin administration and the blood glucose level 240 
was measured using the glucometer mentioned. Plasma insulin concentrations were measured via 241 
an insulin-EIA Test kit (Arbor Assays, MI, USA). The treatment strategy is described in Table 1. 242 
All animal experiments throughout this study were approved by the Research Ethics Committee 243 
(reference number 0003/17, Department of Pharmacy, Southern University Bangladesh) and 244 
conducted according to the Southern University Bangladesh policy for the protection of 245 
Vertebrate Animals used for Experimental and Other Scientific Purposes, with implementation 246 
of the principle of the 3Rs (replacement, reduction, refinement). No skin reactions to MNs 247 
occurred. 248 
Pharmacodynamic and pharmacokinetic profile of insulin-coated 3D printed MNs 249 
The minimum glucose level (Cmin) and the time point of minimum glucose level (Tmin) were 250 
calculated from the plasma glucose level versus time curve. The relative pharmacological 251 
availability (RPA) was calculated using equation 1.  252 
RPA(%) = (AAC3DMN×dosesc)/ (AACsc× dose3DMN) × 100                            (Eq.1) 253 
Where AAC3DMN indicates the area above the curve after the application of the insulin-coated 254 
3D printed MNs, and AACsc shows the area above the curve after the subcutaneous injection of 255 
insulin.  256 
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The maximum plasma insulin concentration (Cmax) and the time point of maximum plasma 257 
insulin concentration (Tmax) were calculated from the plasma insulin concentration (µIU/ml) 258 
versus time curve. The relative bioavailability (RBA) was determined using equation 2. 259 
RBA(%)=(AUC3DMN × dosesc)/ (AUCsc × dose3DMN) × 100                       (Eq.2) 260 
Where AUC3DMN indicates the area under the curve after the application of the insulin-coated 261 
3D printed MNs, and AUCsc shows the area under the curve after the subcutaneous injection of 262 
insulin. 263 
Results and Discussion 264 
Additive Manufacturing and printability of microneedles 265 
MN arrays featuring pyramid and spear needles were 3D printed using a commercial SLA printer 266 
based on digital CAD designs developed via appropriate engineering software. The polymer 267 
employed was a photo-sensitive Class I resin which has been FDA approved. All arrays were 268 
washed and subsequently cured under UV radiation in a controlled temperature environment to 269 
improve the material’s mechanical performance. 270 
The capability of 3D printing technology to manufacture complex structures reproducibly and 271 
accurately in a one-step-fashion, was exploited in this work to build different designs of MN 272 
arrays. Although the degree of complexity that can be achieved through 3D printing is often not 273 
achievable through many conventional techniques of MN manufacturing, the technology is 274 
hampered by restrictions in terms of resolution that can affect the formation of sharp MN tips. 275 
Conventional low-budget SLA printers have a maximum resolution of 100 microns that is 276 
governed by the size of the laser focal point and restricts the minimum size of MN tip that can be 277 
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formed. The MNs designed in the framework of this study featured a tip of 100 microns by 278 
design and their penetration capability through porcine skin was tested to verify that they will 279 
successfully and painlessly pierce the skin. 280 
The printability of MNs was further improved when printing-in-an-angle was implemented, 281 
leading to finer, sharper MN tips. An innate characteristic of the SLA technology is the 282 
interdependence between the print quality and the cross-sectional area in the z-axis; the smaller 283 
the z-axis cross-sectional area, the better the quality. This stems from the peel-off function of the 284 
printing process, according to which, after the completion of each layer, a wiper slides and peels 285 
the structure off the bottom of the resin tank. Larger z-axis cross sectional areas lead to greater 286 
forces applied by the wiper, which can deform the printed structures. Orienting the part to 287 
minimise the contact area of the structure to the resin tank avoids the possible distortions during 288 
the peel-off process and leads to better print quality.  289 
SLA parts are considered mechanically isotropic which ensures the mechanical properties of the 290 
arrays are not affected by the angle of printing. In addition, an influential factor of the 291 
mechanical performance of the MN arrays is the selection of post-process curing parameters 292 
(time and temperature). Further research is required to determine the effect of those factors on 293 
the overall mechanical and piercing behaviour of the MN arrays. In this work, the MNs were 294 
cured in a UV chamber for 60 min in temperature of 40 oC. It is demonstrated in this study that 295 
those parameters yielded systems that successfully pierced through porcine skin requiring small 296 
forces, with no needle failure occurring. 297 
As discussed above due to technical limitations of the existing MN manufacturing techniques 298 
(e.g. moulding, lithography) such as limited drug loading, dose consistency and scalability issues 299 
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there are no commercialized products. Polymeric MNs are fabricated using moulding approaches 300 
while metal MNs implement dip – coating techniques which renders both approaches impractical 301 
for large scale manufacturing. In contrast scale-up of SLA printed MNs is directly related to the 302 
usage of large volume printers or the in-line arrangement of existing printers.  We envisage that 303 
the implementation of SLA printed MNs will open new horizons for transdermal drug delivery 304 
due to the low cost of the printers, printing inks and fast fabrication times.  305 
SEM analysis demonstrated that through the use of the SLA technology, uniform and 306 
reproducible arrays were developed (Fig. 1a,b). In Fig. 1, the high consistency and 307 
reproducibility of the MN layers is depicted, and the formation of sharp tips is demonstrated. It is 308 
evident, that the high-resolution capabilities of the printer allowed the parallel fabrication of 309 
identical and reproducible arrays with characteristics that favour the skin insertion. 310 
Coating of microneedles through inkjet printing 311 
Insulin and sugar alcohol coatings were formed on the surface of the 3D printed MNs using 312 
inkjet printing and a piezoelectric dispenser. A similar process was developed in earlier studies 313 
for coating metallic MNs [16,27], where the applied voltage (mV) and pulse duration (ms) were 314 
tuned to achieve the production of droplets of 300 pL volume with particle size of 100-110 μm. 315 
Fig. 1c,d illustrates the uniformity and reproducibility of the coatings on the MN surface without 316 
any losses of material in the form of satellite droplets on the substrate. Moreover, it is 317 
demonstrated that the consecutive jetting cycles produced drug-containing films that are smooth 318 
and level in comparison to other techniques such as dip coating that may yield voluminous and 319 
inconsistent coatings. This smooth morphology of the films prevents the losses of drug during 320 
MN insertion that occur when bulky coatings remain on the skin surface. 321 
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The drug carriers selected were two alcohol sugars (xylitol, mannitol) and a disaccharide 322 
(trehalose). Those excipients have been reported to favour the immediate coating dissolution in 323 
the skin and to enhance insulin stability in solid state [28–30] . 324 
X-Ray Computer Micro Tomography 325 
The coated 3D printed pyramid MN arrays were scanned using the Bruker Skyscan 1172 and an 326 
overview of the array is presented in Fig. 2a. For sample A, an average needle base area of 1.095 327 
mm2 and an average needle height of 1.034 mm were measured. For samples B and C, the 328 
average needle base areas were measured as 1.065 mm2 and 1.091 mm2 and the average needle 329 
heights as 1.040 mm and 1.038 mm, respectively. The average interspacing of the pyramids 330 
between the centre points was 1.842 mm, 1.865 mm, and 1.864 mm between columns, and 1.788 331 
mm, 1.810 mm, and 1.796 mm between rows for samples A, B and C respectively. Scans taken 332 
from the left-hand side of the arrays illustrate the thin coating films fabricated through inkjet 333 
printing, in comparison with respective ones taken from the back side of the array (Fig. 2b,c). 334 
The relative density of the MNs relative to the control sample (uncoated 3D printed pyramid 335 
MNs) showed an increase of approximately 200 HU between all coated samples and the control 336 
(Fig. 3a,b). Profile lines across a row of MNs revealed a coffee-ring effect in the density of the 337 
coating material deposition. While denser material was distributed randomly within each of the 338 
MNs, a fringe layer of 10-15 μm was apparent with the effect being most pronounced in the 339 
insulin:xylitol coated sample (Fig. 3c).  340 
Penetration experiments in 8-ply strips of parafilm were performed applying a 5 N force (Fig. 4). 341 
The penetration depth was measured as 559 μm, 662 μm and 650 μm for samples A, B and C, 342 
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respectively. The μCT scans illustrate that the coating stays on the MN surface throughout the 343 
piercing process and there is no material remaining on the parafilm surface.  344 
Circular Dichroism 345 
Circular dichroism (CD) spectroscopy is a reliable technique for the evaluation of the secondary 346 
structure of proteins in a solution. The influence of the two polyols and the disaccharide on 347 
insulin molecule as well as their interactions were studied using CD and the estimation of insulin 348 
secondary structure was performed by CDSSTR method [31,32]. 349 
The far-UV CD spectra of insulin and insulin-sugar films (Fig. 5a) were found to be coincident 350 
with the one of standard insulin solution, showing double minima around 210 and 222 nm which 351 
are typical of predominant α-helix structure proteins as already reported elsewhere [28,33–35]. 352 
However, a slight decrease in Molar ellipticity is noted when insulin solution is dried which is 353 
also supported by the decrease of the estimated percentage of α-helix and increase of the β-sheet 354 
content. Such behaviour may be indicative of the unfolding tendency of insulin during 355 
dehydration [36]. Interestingly, once the sugars were added, all the respective insulin-sugar films 356 
spectra showed higher Molar intensities than the insulin film alone, indicating an increase in the 357 
α-helix content. The protective property of those sugars can be explained by the water 358 
replacement mechanism which proposes that sugars may maintain the three-dimensional 359 
structure of proteins by hydrogen-bonding with them [37,38] 360 
Among the tested sugars, xylitol presented the best capability to maintain insulin in its native 361 
secondary structure with even higher amounts of α-helix content. The reason for this still remains 362 
unclear and further research is needed. 363 
Raman Spectroscopy 364 
18 
 
In this work, the Raman spectrum of native insulin shows a strong peak at 1661 cm-1 due to the 365 
amide I mode of α-helix structure and a shoulder at 1682 cm-1 which is attributed to random coil 366 
form as previously reported by Yu et al. [40]. Distinctive peaks of sugars were not found in 367 
Raman mainly because insulin was 5 times more concentrated than the sugars in the films. 368 
Likewise, the amorphous nature of the dried formulation (XRD analysis - data not shown) is 369 
unlikely to afford a strong Raman signal.  370 
Overall, insulin-sugar formulations showed similar Raman spectra to the native insulin (Fig. 5b). 371 
Nonetheless, a slight shift in amide I band position can be seen for all formulations. Amide I 372 
band of insulin-xylitol and insulin-mannitol formulations was shifted towards greater frequency, 373 
1663 cm-1 and 1662 cm-1, respectively, while insulin-trehalose band was shifted to lower 374 
frequency at 1658 cm-1. Those events were also reported by Carpenter and Crowe [37] and 375 
Souillac et al. [41], who described that those changes might be due to the different effect of each 376 
sugar on the vibrational spectra of insulin as well on the hydrogen bonding and couplings 377 
between the adjacent peptide units.  378 
Many researchers have investigated the protective properties of different sugars on polypeptides, 379 
proteins and biomolecules [42–44]. It has been advocated that protein aggregation and 380 
denaturation can be prevented by using carbohydrates as protectants. Protein protection by the 381 
sugars in a dried system can be explained by the water replacement mechanism which suggest 382 
the sugars may substitute water molecules around the biomolecules of proteins, maintaining its 383 
three-dimensional structure by providing sites with hydrogen-bonding species [37,45,46].   384 
Zeng et al. studied the impact of relative humidity (RH) on dehydration of insulin crystals and 385 
they found the hydration water from insulin crystal can be gradually excluded when the RH is 386 
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decreased. They used the high frequency region in Raman spectroscopy to access the band at 387 
~3450cm-1 which is caused by both water and amino acid residues with O-H groups. A 388 
continuous dropping of the O-H stretching band around 3450 cm-1 was observed while the RH 389 
was reduced, indicating dehydration of the molecule [47]. 390 
From Fig. 5b it can be seen that for all formulation the S-S vibration bands are located close to 391 
513 cm-1 suggesting that all disulphide bonds are in an adopted more stable gauche – gauche - 392 
gauche conformation [47,48] as a result of the complete water removal during inkjet printing. 393 
Tyr residues present Raman peaks at 642, 828, 852, and 1174 cm−1, while the 1206 cm−1 peak is 394 
related to both Tyr and Phe residues. Furthermore, the ratios of I852/I828 and I1174/I1206 varied from 395 
0.91 – 1.02 and 0.77 – 0.81 respectively.  These values are much lower compared to those 396 
observed from Zeng et al. [47], for insulin crystals at very low RH (2%). This phenomenon 397 
suggests significant water loss of the coated formulation and stronger H – bonding interactions.  398 
Vibrational modes in the area of 1100 – 1300 cm-1 have shown to be sensitive to the changes of 399 
hydrogen bonds which involve the phenolic hydroxyl groups of Tyr residues and particularly the 400 
7á frequency. In Fig. 5b the 7á has a frequency of 1275cm-1 which is a robust evidence that the 401 
phenolic OH group of Tyr is strongly hydrogen bonded to a base atom [49].  402 
Penetration studies through porcine skin 403 
The 3D printed pyramid and spear shaped MN arrays were tested for their porcine skin 404 
penetration capability using a texture analyser. Identical experiments were performed using 405 
metallic MNs and the results were compared to the respective ones obtained from the 3D printed 406 
MN experiments. All piercing tests were successful with no MN damage or failure. Throughout 407 
each test, measurements of force and displacement were taken (Fig. 6a). 408 
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All curves presented an initial linear segment (displacement < 0.3 mm); after that, the slope was 409 
changing constantly until a maximum force value was reached and a steep decrease of the force 410 
was observed. This value is identified as the maximum force required for MN insertion [26]. The 411 
non-linear behaviour of the force-displacement curve indicates that the process of MN insertion 412 
to the skin is comprised of small penetrations where the MNs gradually tear the skin, before the 413 
load reaches the maximum value that makes the insertion abrupt [50]. The maximum force 414 
required for the MNs to successfully pierce the skin plays a crucial role when different MN 415 
designs need to be compared. As presented in Fig. 6b, the pyramid MN required the least amount 416 
of force to penetrate the porcine skin. 417 
Axial force mechanical testing of MNs 418 
The two studied MN designs were tested under compressive axial loading to determine the force 419 
of microneedle fracture as a function of geometry. The force vs displacement measurements and 420 
respective fracture strength values are presented in Fig. 7.   421 
The two designs exhibited different mechanical behaviours during testing. For both designs, the 422 
recorded force increased until the ultimate load was reached, and fracture occurred. For the spear 423 
MNs, the point of fracture appears as a peak at approximately 175 N, followed by a drop of the 424 
recorded load; as the MNs were kept being pressed against the metal block after fracture, the 425 
load was considerably decreased. On the contrary, the pyramid geometry showed a discontinuity 426 
at approximately 457 N which is identified as the point of initial needle failure. Afterwards, the 427 
load kept increasing as the microneedles kept being compressed. This difference in mechanical 428 
behaviour is attributed to the different modes of needle failure. On the one hand, the spear MNs 429 
fractured in the lateral direction, perpendicular to the loading axis, a finding that was confirmed 430 
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by visual observation. This mode of failure was expected, due to the small thickness of the MNs 431 
in that direction, which translates to minimisation of area, thus increased stress fields. On the 432 
other hand, the pyramid MNs failed under pure compression, with the tip failing first and 433 
additional, increasing force required for the compression of the remaining MN body. These 434 
findings verify that both designs are safe for application since the fracture strengths of the arrays 435 
are far greater than the respective forces needed for needle penetration through porcine skin. 436 
They also confirm that the pyramid geometries present the best potential between the two studied 437 
designs. 438 
In vitro release of insulin through porcine skin 439 
The in vitro insulin release studies from 3D printed pyramid and spear MNs were investigated 440 
using porcine skin in Franz cells. The used carriers, mannitol, trehalose and xylitol not only 441 
preserved insulin in its native form but also provided fast dissolution rates.  As shown in Fig. 442 
8a,b for the pyramid designs approximately 80% of insulin was released in the first 2 min with 443 
86 – 92% within 8 min. The rapid release profiles were obtained for all insulin carriers and no 444 
statistical difference was observed (two-tail p = 0.0021).   445 
The coating of each pyramid side resulted to higher surface area exposed for hydration and thus 446 
faster hydration rates. In contrast, the spear 3D printed designs presented slightly slower insulin 447 
release rates with 62 – 70% and 81 – 84% released within 2 min and 8min respectively. Overall, 448 
the rapid insulin release rates of the 3D printed MNs was attributed to the hydrophilic nature of 449 
the three carriers and the thin coating layers (10 – 15μm) as shown from the μCT analysis. 450 
In vivo transdermal delivery of insulin in diabetic mice 451 
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Diabetes was successfully induced in mice after 7 days of streptozotocin administration. The 452 
preliminary diabetes (hyperglycemia) was demonstrated as 340 ± 10 mg/dl. The diabetic mice 453 
were divided into three groups: Untreated (negative control), subcutaneously (SC) injected 454 
(positive control) and treated with the 3D printed insulin-coated MNs. Fig. 9 shows the 455 
application process of the 3D printed MN arrays. 456 
The dose 0.2 IU/array was selected in order to avoid hypoglycaemia in mice for 4 h. The 457 
comparative studies on different delivery strategies in plasma glucose levels are shown in Fig. 458 
10a. Insulin-coated 3D printed MN arrays showed a remarkable steady state hypoglycaemia 459 
effect (32.8% from total value) in comparison to negative and positive control. After an hour, 460 
subcutaneous injection (0.2 IU/injection) facilitated a rapid increase in insulin concentration in 461 
blood and hence the decrease in plasma glucose level was approximately 30.1% from its primary 462 
value. A comparable blood glucose regulation was observed between the SC group and the MN 463 
group which was achieved within 1 h [51]. Interestingly, the 3D printed patch presented the same 464 
rate to reach its lowest glucose level compared to the SC injection. In similar study 465 
biodegradable MN patches Tmin of glucose levels was achieved within 2 h with administrated 466 
doses of 5 – 10 IU per patch [13]. The main reason for the faster glucose rates is that in Zhang et 467 
al.  (2018) insulin was encapsulated in moulded MN patches while for the 3D printed patches is 468 
applied on the microneedle surface with very hydrophilic thin layers resulting in rapid insulin 469 
release. Moreover, previous studies have shown that microneedle injection of insulin to human 470 
diabetic subjects was chosen over hypodermic infusion and that pharmacokinetics were faster 471 
when insulin was administered to the skin compared to the subcutaneous injections [52]. 472 
Although the plasma glucose level versus time profile was similar to previous findings [53–57] 473 
the steady state plasma glucose level was maintained up to 4 h while the untreated group 474 
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(negative control) remained unchanged (no hypoglycaemia) for the same period. These findings 475 
suggest that insulin is being released from the 3D printed MNs to the mice blood stream via 476 
passive diffusion to blood capillary.  477 
Fig. 10b illustrates the plasma insulin concentration versus time where both SC and 3D printed 478 
MN groups achieved the highest amount of plasma insulin concentration after 1 h of 479 
administration. The control group did not show any detectable plasma insulin concentration. The 480 
highest insulin level of the 3D printed MNs is slightly lower to the SC injection but no statistical 481 
difference was observed. As shown in Fig. 10b after post – administration for 4 h the serum 482 
insulin of 3D printed microneedles was higher to the SC injection.  483 
Tables 2 and 3 represent the pharmacodynamic parameters of plasma glucose levels and the 484 
pharmacokinetic parameters for plasma insulin concentrations, respectively. The RPA and RBA 485 
for the insulin-coated 3D printed MNs group were both about 85-96%. These results indicate that 486 
insulin released from 3D printed MNs was almost completely absorbed from the skin into the 487 
systemic circulation, and the pharmacological activity of the released insulin remained intact 488 
after the delivery with the 3D printed MNs. 489 
Conclusions 490 
MN arrays of high quality and reproducibility, featuring spear and pyramid-shaped needle 491 
geometries, were successfully fabricated by a biocompatible resin using stereolithography. The 492 
3D printed polymeric MNs required low forces to penetrate porcine skin, in comparison with 493 
metallic MNs. Uniform and accurate insulin-sugar thin layers were applied on the surface of the 494 
MNs through inkjet printing, with no satellite droplets detected on the substrate. The insulin 495 
integrity was found to be preserved by all carriers, namely the α–helix and β-Sheet, with xylitol 496 
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showing the optimum performance. In vivo animal trials demonstrated that 3D printed MNs 497 
facilitate rapid low glucose levels with longer duration compared to SC injections.  498 
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 499 
FIGURES 500 
 501 
Figure 1. SEM images of the 3D printed MNs. (a) Uncoated pyramid; (b) uncoated spear; (c) 502 
coated pyramid; (d) coated spear. The thin coating films on the MNs were created using an inkjet 503 
printer. The formulations employed for the coatings contained insulin and a sugar used as a 504 
carrier (xylitol, mannitol and trehalose) in a 5:1 ratio. Each MN patch was coated with 10 IU. All 505 
insulin-carrier combinations formed coatings with similar morphology. The carrier used for 506 
captions (c) and (d) is xylitol.  507 
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 508 
 509 
Figure 2. μCT images of the pyramid MN arrays coated with insulin:xylitol formulation. 510 
(a) Overview; (b) image taken from the back side; (c) image taken from the left-hand side of the 511 
array, showing the thin film coating. 512 
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 513 
Figure 3. μCT evaluation. (a) Profile lines, measured across a single row of the control sample 514 
(uncoated array) and (b) the coated pyramid MN array with insulin:xylitol formulation, showing 515 
a 200 HU increase; (c) cross-section of the coated MN array showing a fringe layer of 10-15 μm.  516 
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  517 
Figure 4. Cross section of MN array penetration through 8-ply strip of parafilm, applying a 5N 518 
load. 519 
520 
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 521 
 522 
 523 
Figure 5. a) CD of insulin and insulin formulations and b) Raman spectra from 500 to 1800 cm-1 524 
of pure insulin and insulin-sugars. 525 
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526 
Figure 6. Penetration studies of MNs through porcine skin, comparing 3D printed spear and 527 
pyramid designs with metallic MNs. (a) Force against displacement curves recorded during MN 528 
insertion tests; (b) Maximum force required for MN penetration. 529 
 530 
Figure 7. MN fracture testing for pyramid and spear designs. (a) Force against displacement 531 
curves recorded during MN fracture tests; (b) Fracture MN strength 532 
 533 
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 534 
Figure 8. In vitro insulin release through porcine skin from a) the pyramid and b) the spear MN 535 
designs for all investigated drug carriers. 536 
 537 
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538 
 Figure 9. Experimental mice (A) before the application, (B) during the application and (C) after 539 
removal of the 3D printed MN array for the delivery of insulin to diabetic mice. 540 
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 541 
Figure 10. a) Comparative plasma glucose level vs time for untreated group, subcutaneous (SC) 542 
injection and insulin-coated 3D Printed MN array applied to diabetic mice, over 4 hours (n=3), 543 
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b) comparative plasma insulin concentration vs time for untreated group, subcutaneous (SC) 544 
injection and insulin-coated 3D Printed MN array applied to diabetic mice, over 4 hours (n=3).  545 
 546 
TABLES 547 
Table 1 Treatment protocol for insulin-coated 3D printed MN array.  548 
Day Stage Treatment strategy  
-7 Animal model selection 
and isolation  
Transfer mice to study isolator 
0 Induction of diabetes • Weigh animals and injected with streptozotocin 
(diabetes inducer) 
• Daily blood glucose measurements 
1  
 
Observation 
 
 
 
Blood glucose level measurements 
2 
3 
4 
5 
6 
7 Confirmation of 
diabetes induction 
Blood glucose level exceeds 300 mg/dl within 7 days.  
8 Antidiabetic therapy 
using insulin-coated 3D 
printed MN array 
After treatment, hourly (up to 4 hours) blood samples 
were collected from the jugular vein and the blood 
glucose level was measured. 
The study was conducted for 24 hours. 
549 
35 
 
 550 
Table 2. Pharmacodynamic parameters for plasma glucose levels of diabetic mice for untreated 551 
groups, subcutaneous (SC) injection (insulin dose: 0.2 IU) and 3D Printed MN array (insulin 552 
dose: 0.2 IU) (n=3).  553 
Group Cmin (%) Tmin (h) AAC0 to 4 (% hr) RPA (%) 
Untreated groups 89.5 ± 4.2 3 22.7 ± 1.2 - 
SC injections 32.8 ± 3.7 1 208.5± 3.7 100 
3D Printed MN arrays 30.1 ± 1.0 1 240.6 ± 2.9 122 
Cmin, minimum glucose level; Tmin, time point of minimum glucose level; AAC0 to 4, area above 554 
the plasma glucose concentration vs. time curve; RPA, relative pharmacological availability 555 
compared to subcutaneous injection.  556 
 557 
Table 3. Pharmacokinetic parameters for plasma glucose levels of diabetic mice for untreated 558 
groups, subcutaneous (SC) injection (insulin dose: 0.2 IU) and 3D Printed MN array (insulin 559 
dose: 0.2 IU) (n=3).    560 
Group Cmax (µIU ml-1) Tmax (h) AUC0 to 4 (µIUhr-1 ml-1) RBA (%) 
Untreated groups 0 0 0 0 
SC injections 63.2 ± 8.8 1 120.5 ± 6.4 100 
3D Printed MN arrays 59.9 ± 7.9 1 147.4 ± 5.8 115 
Cmax, maximum plasma insulin concentration; Tmax, time point of maximum plasma insulin 561 
concentration; AUC0 to 4, area under the plasma insulin concentration vs. time curve; RBA, 562 
relative bioavailability compared with subcutaneous injection. 563 
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